$SRNE "The CEO overhyping in vitro data (not even pre-clinical animal data) is a red flag" Agreed. SRNE will be a good short (especially with their abysmal current ratio- an offering right about now seems likely). That said, I believe it will run for 2-3 more days as most of the hyped COVID plays seem to.